| Neyns, Bart |
COMBI-R2, NCT03754179: Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma |
|
|
| Recruiting | 2 | 63 | Europe | Dabrafenib, Tafinlar, DAB, Trametinib, Mekinist, TRA, Hydroxychloroquine, Plaquenil, HCQ | Universitair Ziekenhuis Brussel, University Hospital, Ghent | Melanoma | 12/21 | 07/22 | | |
| Completed | 2 | 45 | Europe | Trametinib, TRA, Mekinist, Dabrafenib, DAB, Tafinlar | Universitair Ziekenhuis Brussel | Stage IV Melanoma, Stage III Melanoma | 06/23 | 06/23 | | |
NCT05529316: A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma |
|
|
| Suspended | 2 | 220 | Europe, US, RoW | Botensilimab, AGEN1181, Balstilimab, AGEN2034 | Agenus Inc. | Advanced Melanoma | 05/28 | 05/28 | | |
Luscid, NCT04571632: Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors |
|
|
| Recruiting | 2 | 36 | Europe | Avelumab, Bavencio, Ipilimumab 5 MG/ML, Yervoy, Pembrolizumab 100 MG in 4 ML Injection, Keytruda, CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC | Universitair Ziekenhuis Brussel | Non Small Cell Lung Cancer, Solid Tumor | 12/23 | 12/23 | | |
1-2018 BSMO, NCT03967938: Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination Genes |
|
|
| Active, not recruiting | 2 | 540 | Europe | Olaparib Oral Capsule | AZ-VUB, AstraZeneca, Kom Op Tegen Kanker | Advanced Cancers Harbouring Mutations in HRG | 12/24 | 12/25 | | |
| Recruiting | 2 | 48 | Europe | Regorafenib 40 MG Oral Tablet, Triplet therapy | Universitair Ziekenhuis Brussel | Melanoma Stage III, Melanoma Stage IV | 12/24 | 03/25 | | |
myDCTV, NCT03747744: Intratumoral Injection of Autologous CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Talimogene Laherparepvec (T-VEC) |
|
|
| Active, not recruiting | 1 | 18 | Europe | CD1c (BDCA-1)+ myDC, intratumoral injection of talimogene laherparepvec (T-VEC) | Universitair Ziekenhuis Brussel | Melanoma | 10/23 | 10/23 | | |
GlitIpNi, NCT03233152: Intra-tumoral Ipilimumab Plus Intravenous Nivolumab Following the Resection of Recurrent Glioblastoma |
|
|
| Active, not recruiting | 1 | 110 | Europe | Ipilimumab (YervoyTM, 50 mg/10 mL solution), Nivolumab (OpdivoTM, 40 mg/4 mL solution), Nivolumab (OpdivoTM, 40 mg/4mL solution) | Universitair Ziekenhuis Brussel | Glioblastoma | 11/23 | 11/23 | | |
CognIT, NCT05667857: Longitudinal Neurocognitive, Psychosocial and Health-related Quality of Life Assessment in Advanced Cancer Survivors Treated With Immunotherapy and the Efficacy of Integrative Neurocognitive Remediation Therapy |
|
|
| Recruiting | N/A | 100 | Europe | Integrative neurocognitive remediation therapy | Universitair Ziekenhuis Brussel, Brugmann University Hospital | Cognitive Remediation, Neuropsychology, Quality of Life, Psycho-Oncology, Cognitive Behavioral Therapy, Cancer Survivors, Immunotherapy, Cognitive Dysfunction, Psychological Distress | 11/24 | 12/33 | | |
ICIT, NCT02673970: Biomarkers for the Activity of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma |
|
|
| Recruiting | N/A | 200 | Europe | | Universitair Ziekenhuis Brussel | Malignant Melanoma | 09/25 | 12/25 | | |
DW-MRi, NCT02907827: Whole-body DW-MRI and cfDNA Analysis for the Surveillance of Melanoma Patients at High Risk for Recurrence. |
|
|
| Recruiting | N/A | 100 | Europe | follow up DW MRI, cfDNA | Universitair Ziekenhuis Brussel | Melanoma | 11/25 | 11/25 | | |
| Recruiting | N/A | 4975 | Europe, RoW | RP-1828 IMMUcan, RP-1759 AYA/TYA, RP-1843 Arcagen, RP-1920 BioRadon | European Organisation for Research and Treatment of Cancer - EORTC | All Tumor Types | 03/26 | 03/26 | | |
| Vandenbossche, Katrien |
ICIT, NCT02673970: Biomarkers for the Activity of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma |
|
|
| Recruiting | N/A | 200 | Europe | | Universitair Ziekenhuis Brussel | Malignant Melanoma | 09/25 | 12/25 | | |
DW-MRi, NCT02907827: Whole-body DW-MRI and cfDNA Analysis for the Surveillance of Melanoma Patients at High Risk for Recurrence. |
|
|
| Recruiting | N/A | 100 | Europe | follow up DW MRI, cfDNA | Universitair Ziekenhuis Brussel | Melanoma | 11/25 | 11/25 | | |
